Back to Peptides
Tesamorelin vs CJC-1295
Growth HormoneTesamorelin and CJC-1295 are both GHRH analogs but occupy different positions in the peptide landscape. Tesamorelin (Egrifta) is the only FDA-approved GHRH analog — approved specifically for HIV-associated lipodystrophy — with strong clinical data on visceral fat reduction. CJC-1295 is a research peptide with modifications for extended half-life, especially the DAC version which provides weekly dosing.
moderate Search Demand
Side-by-Side Comparison
| Aspect | Tesamorelin | CJC-1295 |
|---|---|---|
| cost | Higher — prescription drug pricing | Lower — research peptide pricing |
| dosing | 2 mg SubQ daily (standard protocol) | 100-300 mcg 2-3x daily (no DAC) or 300-1000 mcg 1-2x weekly (with DAC) |
| best for | Visceral fat reduction, abdominal fat, metabolic syndrome, those wanting FDA-approved option | Sustained GH elevation, anti-aging, body composition, stacking with GH secretagogues |
| mechanism | 44-amino-acid GHRH analog — rapid GH pulse, specifically studied for visceral fat reduction | Modified GHRH (1-29) — engineered for protease resistance; DAC version binds albumin for 6-8 day half-life |
| fda status | FDA-approved (Egrifta SV) for HIV-associated lipodystrophy | Not FDA-approved; research peptide |
| side effects | Injection site reactions, joint pain, paresthesia, elevated IGF-1 | Flushing/head rush, water retention (more with DAC) |
| clinical evidence | Strong — multiple Phase 3 trials, FDA-approved, proven visceral fat reduction | Limited — Phase 2 data available, not FDA-approved |
Verdict
Tesamorelin for visceral fat and FDA-regulated safety. CJC-1295 with DAC for convenient weekly dosing and sustained GH. Tesamorelin has the clinical evidence advantage; CJC-1295 DAC has the convenience advantage.